/
OBIO
$4.75+$0.51 (+12.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$253.9M
60M shares
52-week range
$2.20 – $5.42
79% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.7M | −$782.0K | $3.5M | $2.8M | $2.6M | $33.5M |
| Cost of revenue | $145.0K | $199.0K | $322.0K | $186.0K | $204.0K | $190.0K |
| Gross profit | $5.6M | −$981.0K | $3.2M | $2.6M | $2.4M | $33.3M |
| Gross margin | 97.5% | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| R&D | $13.5M | $12.9M | $21.9M | $33.8M | $42.8M | $58.2M |
| Operating income | −$18.8M | −$21.8M | −$32.7M | −$51.5M | −$64.3M | −$51.8M |
| EBITDA | −$18.6M | −$21.9M | −$33.4M | −$48.8M | −$60.7M | −$51.2M |
| Net income | −$21.4M | −$23.0M | −$33.6M | −$49.1M | −$61.0M | −$52.7M |
| Net margin | -374.5% | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (diluted) | -0.01 | -0.02 | -1.32 | -1.48 | -1.66 | -1.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $548286 | $-1.56 | $-1.70–$-1.38 | 5 |
| 2027 | $655429 | $-1.45 | $-1.66–$-1.17 | 5 |
| 2028 | $15M | $-0.87 | $-1.08–$-0.57 | 3 |
| 2029 | $54M | $-0.27 | $-0.52–$-0.17 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Orchestra BioMed Holdings, Inc. Ordinary Shares
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
www.orchestrabiomed.com- Employees
- 86
- IPO / List date
- Jan 27, 2023
- HQ
- NEW HOPE, PA
Held by traders on TradeandTell
No one on the platform currently holds OBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 70,900 | $301.3K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OBIO yet.
